Table 3.

Population-based studies evaluating survival with warfarin compared with other anticoagulants in patients with cancers.

	Data sources	Study period	Population	Cancer types	N	Adjusted hazard ratio for cancer-related or overall mortality (95%CI)
Kinnunen 2017[32]	Finnish Cancer Registry and national reimbursement database	1995 - 2015	Men aged 55-67	Prostate	1074 Warfarin 978 Other AC	Warfarin users vs. non-warfarin AC users: 1.01 (0.71-1.44)
Kinnunen 2019[34]	Finnish Cancer Registry and national reimbursement database	1995 - 2016	Men aged 55-67	Lung, gastric, colorectal, CNS, NHL, hepatic, pancreatic, renal, bladder	17826 Warfarin 12326 LMWH 8595 Other AC	Warfarin users vs. non-warfarin AC users: 0.45 (0.41 – 0.50)*
Kinnunen 2020 [35]	Finnish Cancer Registry and national reimbursement database	1995 - 2015	Women median age 59 – 72	Breast	914 Warfarin 906 Other AC	Warfarin users vs. non-warfarin AC users: 0.88 (0.80 – 0.98)*
Chiasakul 2021 [36]	SEER-Medicare	2007 - 2016	Aged ≥66 with VTE	Gastric, colorectal, pancreatic, lung, ovarian, or brain	4853 LMWH 4853 Warfarin	Warfarin vs. LMWH: 0.86 (0.83 – 0.90)*

RR, rate ratio; HR, hazard ratio; AC, anticoagulant; VTE, venous thromboembolism

^*denotes statistically significant results